Showing 1 - 20 results of 2,204 for search '(( ct ((((largest decrease) OR (larger decrease))) OR (marked decrease)) ) OR ( 34 1 decrease ))', query time: 0.50s Refine Results
  1. 1
  2. 2

    Participant characteristics (<i>n</i> = 34). by Yong-Rae Kim (19797278)

    Published 2024
    “…<div><p>This study demonstrated the effect of differences in the exterior of erosion control dams (ECDs) on humans. We recruited 34 university students. Participants sat 1.4 m away from the display while wearing a device for measuring heart rate (HR) and heart rate variability. …”
  3. 3

    Infection of CD 34 by Ancy Joseph (5634794)

    Published 2025
    “…Survival curve of HTLV-1-p12stop, and HTLV-1-CTCF infected CD34+ Hu-mice. …”
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Chromatin accessibility analysis of perinatal Vps34-deficient Tregs. by Erienne G. Norton (9612079)

    Published 2025
    “…AP-1-related transcription factors with predicted decreased activity are labeled. …”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Vps34 is essential for terminal differentiation of eTregs during perinatal life. by Erienne G. Norton (9612079)

    Published 2025
    “…(<b>F</b>) GSEA enrichment plots showing increased Vps34-activated signature (upper; i.e., top 200 downregulated genes [log<sub>2</sub>FC < −0.5, <i>P</i> < 0.05]) in Vps34-deficient Tregs versus control Tregs from mixed BM chimeras; see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#pbio.3003074.s010" target="_blank">S2 Table</a> and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#sec010" target="_blank">Materials and methods</a> for details) and decreased Vps34-suppressed signature (lower; i.e., top 200 upregulated genes [log<sub>2</sub>FC > 0.5, <i>P</i> < 0.05]) in Vps34-deficient Tregs versus control Tregs from mixed BM chimeras; see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#pbio.3003074.s010" target="_blank">S2 Table</a> and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#sec010" target="_blank">Materials and methods</a> for details) in KLRG1<sup>+ </sup>Nfil3<sup>+</sup> terminal Tregs compared to KLRG1<sup>− </sup>Nfil3<sup>+</sup> transitional Tregs (from a public RNA-seq dataset GSE130884 [<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#pbio.3003074.ref011" target="_blank">11</a>]; see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003074#sec010" target="_blank">Materials and methods</a> for details). …”
  18. 18
  19. 19

    Design, Synthesis, and Biological Evaluation of [1,2,5]Oxadiazolo[3,4‑<i>b</i>]pyridin-7-ol as Mitochondrial Uncouplers for the Treatment of Obesity and Metabolic Dysfunction-Assoc... by Mary A. Foutz (20361830)

    Published 2024
    “…In this study, we disclose the structure–activity relationship profile of 6-substituted [1,2,5]oxadiazolo[3,4-<i>b</i>]pyridin-7-ol derivatives of BAM15. …”
  20. 20